Wei Tong

US Patent:

7312223, Dec 25, 2007

Filed:

Jul 29, 2004

Appl. No.:

10/901574

Inventors:

Anima Ghosal - Edison NJ, US
Wei Tong - New City NY, US
Swapan K. Chowdhury - Warren NJ, US
Shmuel Zbaida - East Brunswick NJ, US
Mark A. Wirth - Neshanic Station NJ, US
Kevin B. Alton - Cedar Knolls NJ, US
James E. Patrick - Aiken SC, US
Craig D. Boyle - Branchburg NJ, US
Andrew Stamford - Chatham Township NJ, US

Assignee:

Schering Corporation - Kenilworth NJ

International Classification:

C07D 473/06
A61K 31/522
A61P 9/10
A61P 9/12

US Classification:

51426334, 544271, 544272, 51426335, 51426336

Abstract:

The present invention is directed to a metabolite of a xanthine Phosphodiesterase type 5 inhibitor having the following structureFurther disclosed are methods of treating a physiological disorder, symptom or disease in a patient, comprising administering to the patient an effective amount of the above compound, wherein the physiological disorder, symptom or disease is a urogenital, cardiovascular, cerebrovascular or peripheral vascular disorder, angina pectoris, hypertension, restenosis post angioplasty, endarterectomy, stent introduction, cerebral stroke, a respiratory tract disorder such as an allergic condition associated with atopy, pulmonary hypertension, an ischemic heart disorder, impaired glucose tolerance, diabetes and its related complication, insulin resistance syndrome, hyperglycemia, polycystic ovarian syndrome, a glomerular disorder, renal insufficiency, nephritis, a tubular interstitial disorder, an autoimmune disorder, glaucoma, intestinal motility, cachexia or cancer.

US Patent:

7507739, Mar 24, 2009

Filed:

Sep 24, 2004

Appl. No.:

10/950543

Inventors:

Nan Zhang - Bayside NY, US
Thai Nguyen - Fair Lawn NJ, US
Yanzhong Wu - Bronx NY, US
Wei Tong - Suffern NY, US

Assignee:

Wyeth - Madison NJ

International Classification:

C07D 487/04
A61K 31/519
A61P 35/04

US Classification:

5142593, 544263

Abstract:

This invention relates to certain 6-[(substituted)phenyl]triazolopyrimidine compounds or pharmaceutically acceptable salts thereof, and compositions containing said compounds or pharmaceutically acceptable salts thereof, wherein said compounds are anti-cancer agents useful for the treatment of cancer in mammals. This invention further relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal and further provides a method for the treatment or prevention of cancerous tumors that express multiple drug resistance (MDR) or are resistant because of MDR, in a mammal in need thereof which method comprises administering to said mammal an effective amount of said compounds or pharmaceutically acceptable salts thereof. The present invention relates to a method of treating or inhibiting the growth of cancerous tumor cells and associated diseases in a mammal in need thereof by promotion of microtubule polymerization which comprises administering to said mammal an effective amount of said compounds and pharmaceutically acceptable salts thereof.

US Patent:

8641948, Feb 4, 2014

Filed:

Mar 19, 2012

Appl. No.:

13/423329

Inventors:

Jennifer Snyder - Morris Plains NJ, US
Wei Quin Tong - Basking Ridge NJ, US
Sudha Vippagunta - Morris Plains NJ, US

Assignee:

Novartis AG - Basel

International Classification:

B29C 47/00
B29C 67/24

US Classification:

264211, 2641761, 26421121, 424465

Abstract:

A process for preparing solid dispersions of highly crystalline compounds. The highly crystalline or thermally labile therapeutic compounds are processed in an extruder in combination with a solubilizing agent and optionally a plasticizer. The resulting extrudate features the therapeutic compound in an amorphous state. Particularly useful as the solubilizing agents are surfactants such as poloxamers.

US Patent:

20070265335, Nov 15, 2007

Filed:

Nov 9, 2006

Appl. No.:

11/558382

Inventors:

WEIGUO LIU - PARSIPPANY NJ, US
QIUXIA WANG - NANUET NY, US
WEI TONG - SUFFERN NY, US
PANOLIL RAVEENDRANATH - MONROE NY, US
SILVIO IERA - MONTREAL, CA

Assignee:

WYETH - Madison NJ
VIROPHARMA INCORPORATED - Exton PA

International Classification:

A61K 31/343
A61P 31/14
C07D 307/78

US Classification:

514469000, 549467000

Abstract:

Substantially pure polymorphic forms of 5-cyclopropyl-2-(4-fluorophenyl)-6-[(2-hydroxyethyl)(methylsulfonyl)amino]-N-methyl-1-benzofuran-3-carboxamide are produced by recrystallization in an organic solvent.

US Patent:

20100297499, Nov 25, 2010

Filed:

May 12, 2008

Appl. No.:

12/600051

Inventors:

Wei Tong - Piscataway NJ, US
Glen Amatucci - Peapack NJ, US

International Classification:

H01M 4/54

US Classification:

429219

Abstract:

The present invention relates to a novel class of silver oxyfluoride based electrode materials based on the perovskite structure used in primary and rechargeable electromechanical energy storage systems.